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I. INTRODUCTION
Heart failure (HF) is a major public health problem in the
United States. Nearly 5 million patients in this country have
HF, and nearly 500,000 patients are diagnosed with HF for
the first time each year. The disorder is the underlying
reason for 12 to 15 million office visits and 6.5 million
hospital days each year (1). During the last 10 years, the
annual number of hospitalizations has increased from ap-
proximately 550,000 to nearly 900,000 for HF as a primary
diagnosis and from 1.7 to 2.6 million for HF as a primary or
secondary diagnosis (2). Nearly 300,000 patients die of HF as
a primary or contributory cause each year, and the number of
deaths has increased steadily despite advances in treatment.
HF is primarily a disease of the elderly (3). Approxi-
mately 6% to 10% of people older than 65 years have HF
(4), and approximately 80% of patients hospitalized with
HF are more than 65 years old (2). HF is the most common
Medicare diagnosis-related group, and more Medicare dol-
lars are spent for the diagnosis and treatment of HF than for
any other diagnosis (5). The total inpatient and outpatient
costs for HF in 1991 were approximately $38.1 billion,
which was approximately 5.4% of the healthcare budget that
year (1). In the United States, approximately $500 million
annually is spent on drugs for the treatment of HF.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) first published guide-
lines for the evaluation and management of HF in 1995 (6).
Since that time, a great deal of progress has been made in
the development of both pharmacological and nonpharma-
cological approaches to treatment for this common, costly,
disabling, and generally fatal disorder. For this reason, the 2
organizations believed that the time was right to reassess
and update these guidelines, fully recognizing that the
optimal therapy of HF remains a work in progress and that
future guidelines will supersede these.
The writing committee was composed of 7 members who
represented the ACC and AHA, as well as invited partici-
pants from the American College of Chest Physicians, the
Heart Failure Society of America, the International Society
for Heart and Lung Transplantation, the American Acad-
emy of Family Physicians, and the American College of
Physicians–American Society of Internal Medicine. Both
the academic and private practice sectors were represented.
This document was reviewed by 3 official reviewers nomi-
nated by the ACC, 3 official reviewers nominated by the
AHA, 1 reviewer nominated by the Heart Failure Society of
America, 1 reviewer nominated by the International Society
for Heart and Lung Transplantation, 1 reviewer nominated
by the American Academy of Family Physicians, 1 reviewer
nominated by the National Heart Foundation of Australia,
the ACC Hypertensive Disease Committee and 16 content
reviewers.
In formulating the present document, the writing com-
mittee decided to take a new approach to the classification
of HF that emphasized both the evolution and progression
of the disease. In doing so, we identified 4 stages of HF.
Stage A identifies the patient who is at high risk for
developing HF but has no structural disorder of the heart;
Stage B refers to a patient with a structural disorder of the
heart but who has never developed symptoms of HF; Stage
C denotes the patient with past or current symptoms of HF
associated with underlying structural heart disease; and
Stage D designates the patient with end-stage disease who
requires specialized treatment strategies such as mechanical
circulatory support, continuous inotropic infusions, cardiac
transplantation, or hospice care (see Table 1 and Fig. 1).
Only the latter 2 stages, of course, qualify for the traditional
clinical diagnosis of HF for diagnostic or coding purposes.
This classification recognizes that there are established risk
factors and structural prerequisites for the development of
HF and that therapeutic interventions performed even
before the appearance of left ventricular dysfunction or
symptoms can reduce the morbidity and mortality of HF.
This classification system is intended to complement but
not to replace the New York Heart Association (NYHA)
functional classification, which primarily gauges the severity
of symptoms in patients who are in stage C or D. It has been
recognized for many years, however, that the NYHA
functional classification reflects a subjective assessment by a
physician and changes frequently over short periods of time
and that the treatments used do not differ significantly
across the classes. Therefore, the committee believed that a
staging system was needed that would reliably and objec-
tively identify patients in the course of their disease and
would be linked to treatments that were uniquely appropri-
ate at each stage of their illness. According to this new
approach, patients would be expected to advance from one
stage to the next unless progression of the disease was
slowed or stopped by treatment. This new classification
scheme adds a useful dimension to our thinking about HF
similar to that achieved by staging systems for other disor-
ders (e.g., those used in the classification of cancer).
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All recommendations provided in this document follow
the format of previous ACC/AHA guidelines:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/
therapy is useful and effective.
Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of performing the
procedure/therapy.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is
not useful/effective and in some cases may be
harmful.
The recommendations listed in this document are evi-
dence based whenever possible. Pertinent medical literature
in the English language was identified through a series of
computerized literature searches (including Medline and
EMBASE) and a manual search of selected articles. Refer-
ences selected and published in this document are represen-
tative but not all-inclusive.
The levels of evidence on which these recommendations
are based were ranked as level A if the data were derived
from multiple randomized clinical trials, level B when data
were derived from a single randomized trial or nonrandom-
ized studies, and level C when the consensus opinion of
experts was the primary source of recommendation. The
strength of evidence does not necessarily reflect the strength
of a recommendation. A treatment may be considered
controversial although it has been evaluated in controlled
clinical trials; conversely, a strong recommendation may be
based on years of clinical experience and be supported only
by historical data or by no data at all.
The committee elected to focus this document on the
prevention of HF, as well as the evaluation and manage-
ment of chronic HF in the adult patient with left ventricular
systolic and diastolic dysfunction. It specifically did not
consider acute HF, which might merit a separate set of
guidelines and which is addressed in part in the ACC/AHA
guidelines for the management of patients with acute
myocardial infarction (7). We have also excluded HF in
children, both because the underlying causes of HF in
children differ from those in adults and because none of the
controlled trials of treatments for HF have included chil-
dren. We have not considered the management of HF due
to primary valvular disease (see ACC/AHA guidelines on
management of patients with valvular heart disease) (8) or
congenital malformations, and we have not included rec-
ommendations for the treatment of specific myocardial
disorders (e.g., hemochromatosis, sarcoidosis, or amyloid-
osis).
The ACC/AHA guidelines for the evaluation and man-
agement of chronic heart failure in the adult were approved
for publication by the governing bodies of the ACC and
AHA. These guidelines will be reviewed annually after
publication and will be considered current unless the
ACC/AHA Task Force on Practice Guidelines revises or
withdraws them from circulation.
Table 1. Stages of HF
Stage Description Examples
A Patients at high risk of developing HF because of
the presence of conditions that are strongly
associated with the development of HF. Such
patients have no identified structural or
functional abnormalities of the pericardium,
myocardium, or cardiac valves and have never
shown signs or symptoms of HF.
Systemic hypertension; coronary artery disease;
diabetes mellitus; history of cardiotoxic
drug therapy or alcohol abuse; personal
history of rheumatic fever; family history of
cardiomyopathy.
B Patients who have developed structural heart
disease that is strongly associated with the
development of HF but who have never shown
signs or symptoms of HF.
Left ventricular hypertrophy or fibrosis; left
ventricular dilatation or hypocontractility;
asymptomatic valvular heart disease;
previous myocardial infarction.
C Patients who have current or prior symptoms of
HF associated with underlying structural heart
disease.
Dyspnea or fatigue due to left ventricular
systolic dysfunction; asymptomatic patients
who are undergoing treatment for prior
symptoms of HF.
D Patients with advanced structural heart disease
and marked symptoms of HF at rest despite
maximal medical therapy and who require
specialized interventions.
Patients who are frequently hospitalized for
HF or cannot be safely discharged from the
hospital; patients in the hospital awaiting
heart transplantation; patients at home
receiving continuous intravenous support
for symptom relief or being supported with
a mechanical circulatory assist device;
patients in a hospice setting for the
management of HF.
HF indicates heart failure.
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These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the prevention, diagnosis, and
management of HF. The guidelines attempt to define
practices that meet the needs of most patients under most
circumstances. However, the ultimate judgment regarding
the care of a particular patient must be made by the
physician in light of all of the circumstances that are relevant
to that patient. The various therapeutic strategies described
in this document can be viewed as a checklist to be
considered for each patient in an attempt to individualize
treatment for an evolving disease process. Every patient is
unique, not only in terms of his or her cause and course of
HF, but also in terms of his or her personal and cultural
approach to the disease. Guidelines can only provide an
outline for evidence-based decisions or recommendations
for individual care; these guidelines are meant to provide
that outline.
II. CHARACTERIZATION OF
HF AS A CLINICAL SYNDROME
HF is a complex clinical syndrome that can result from any
structural or functional cardiac disorder that impairs the
ability of the ventricle to fill with or eject blood. The
cardinal manifestations of HF are dyspnea and fatigue,
which may limit exercise tolerance, and fluid retention,
which may lead to pulmonary and peripheral edema. Both
abnormalities can impair the functional capacity and quality
of life of affected individuals, but they may not necessarily
dominate the clinical picture at the same time.
Coronary artery disease is the underlying cause of HF in
approximately two thirds of patients with left ventricular
systolic dysfunction (9). The remainder have nonischemic
causes of systolic dysfunction and may have an identifiable
cause (e.g., hypertension, valvular disease, myocardial tox-
ins, or myocarditis) or may have no discernible cause (e.g.,
idiopathic dilated cardiomyopathy).
The classification system that is most commonly used to
quantify the degree of functional limitation imposed by HF
is one first developed by the NYHA (10). This system
assigns patients to 1 of 4 functional classes depending on the
degree of effort needed to elicit symptoms: patients may
have symptoms of HF at rest (class IV), on less-than-
ordinary exertion (class III), on ordinary exertion (class II),
or only at levels that would limit normal individuals (class I).
The mechanisms responsible for exercise intolerance in
patients with chronic HF have not been clearly defined.
Patients with a very low ejection fraction may be asymp-
tomatic, whereas patients with preserved left ventricular
systolic function may have severe disability. The apparent
discordance between the severity of systolic dysfunction and
the degree of functional impairment is not well understood
despite intense investigation.
Left ventricular dysfunction begins with some injury to
Figure 1. Stages in the evolution of HF and recommended therapy by stage. FHx CM indicates family history of cardiomyopathy; MI, myocardial
infarction; LV, left ventricular; and IV, intravenous.
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the myocardium and is usually a progressive process, even in
the absence of a new identifiable insult to the myocardium.
The principal manifestation of such progression is a process
known as remodeling, which occurs in association with
homeostatic attempts to decrease wall stress through in-
creases in wall thickness. This ultimately results in a change
in the geometry of the left ventricle such that the chamber
dilates, hypertrophies, and becomes more spherical. The
process of cardiac remodeling generally precedes the devel-
opment of symptoms, occasionally by months or even years.
The process of remodeling continues after the appearance of
symptoms and may contribute importantly to worsening of
symptoms despite treatment.
The committee struggled with its perception that many
clinicians do not appreciate the progressive nature of left
ventricular dysfunction and HF or the importance of screen-
ing and prophylaxis for them, principles that are quite
analogous to well-recognized strategies in the field of
oncology. For this reason, it believed that the progression to
and evolution of HF could appropriately be characterized by
considering 4 stages in the evolution of the disease as
described in the Introduction and Table 1. This classifica-
tion scheme recognizes that HF, like coronary artery dis-
ease, has established risk factors; that the evolution of HF
has asymptomatic and symptomatic phases; and that treat-
ments prescribed at each stage can reduce the morbidity and
mortality of HF.
III. ASSESSMENT OF PATIENTS
A. Initial Evaluation of Patients and
Detection of Predisposing Conditions
1. Identification of Patients. In general, patients with left
ventricular dysfunction present to the physician in 1 of 3
ways: with a syndrome of decreased exercise tolerance; with
a syndrome of fluid retention; or with no symptoms and
incidentally discovered left ventricular dysfunction.
2. Identification of Structural Abnormality. A complete
history and physical examination are the first steps in
evaluating the structural abnormality or cause responsible
for the development of HF. Although the history and
physical examination may provide important clues about the
nature of the underlying cardiac abnormality, identification
of the structural abnormality leading to HF generally
requires either noninvasive or invasive imaging of the
cardiac structures. The single most useful diagnostic test in
the evaluation of patients with HF is the 2-dimensional
echocardiogram, coupled with Doppler flow studies. Other
tests may be used to provide information regarding the
nature and severity of the cardiac abnormality. Radionuclide
ventriculography can provide highly accurate measurements
of global and regional function and assessment of ventricular
enlargement, but it is unable to directly assess valvular
abnormalities or cardiac hypertrophy. Both chest radiogra-
phy and 12-lead electrocardiograms are considered to pro-
vide baseline information in most patients, but because they
are both insensitive and nonspecific, neither the chest
radiograph nor the electrocardiogram alone should form the
primary basis for determining the specific cardiac abnormal-
ity responsible for the development of HF.
Recently, the measurement of circulating levels of brain
natriuretic peptide has become available as a means of
identifying patients with elevated left ventricular filling
pressures who are likely to exhibit signs and symptoms of
HF. The assessment of this peptide cannot reliably distin-
guish patients with systolic from those with diastolic dys-
function. However, it has been widely investigated as a
biochemical marker of morbidity and mortality in patients
with known HF (11) and as an aid in differentiating dyspnea
due to HF from dyspnea due to other causes in an
emergency setting (12). The role of brain natriuretic peptide
measurement in the identification and management of
patients with symptomatic or asymptomatic left ventricular
dysfunction remains to be fully clarified.
3. Evaluation of the Cause of Ventricular Dysfunction.
Identification of the disorder leading to HF may be impor-
tant, because some causes of left ventricular dysfunction are
reversible or treatable. However, it may not be possible to
discern the cause of HF in many patients who present with
this syndrome, and in others, the underlying condition may
not be amenable to treatment. Hence, physicians should
focus their efforts on diagnoses that have some potential for
improvement with therapy directed at the underlying con-
dition. Evaluation of potential causative factors should
include taking a patient and family history, general labora-
tory testing, evaluation of the possibility of coronary artery
disease, and evaluation of the possibility of primary myo-
cardial disease.
B. Ongoing Evaluation of HF
Once the nature and cause of the structural abnormalities
leading to the development of HF have been defined,
physicians should focus on the clinical assessment of pa-
tients, both during the initial presentation and during
subsequent visits. This ongoing review of the patient’s
clinical status is critical to the appropriate selection and
monitoring of treatment. It should include assessment of
functional capacity, assessment of volume status, laboratory
evaluation, and assessment of prognosis.
Recommendations for the Evaluation of Patients With HF
Class I
1. Thorough history and physical examination to
identify cardiac and noncardiac disorders that
might lead to the development of HF or accelerate
the progression of HF. (Level of Evidence: C)
2. Initial and ongoing assessment of patient’s ability
to perform routine and desired activities of daily
living. (Level of Evidence: C)
3. Initial and ongoing assessment of volume status.
(Level of Evidence: C)
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4. Initial measurement of complete blood count, uri-
nalysis, serum electrolytes (including calcium and
magnesium), blood urea nitrogen, serum creatinine,
blood glucose, liver function tests, and thyroid-
stimulating hormone. (Level of Evidence: C)
5. Serial monitoring of serum electrolytes and renal
function. (Level of Evidence: C)
6. Initial 12-lead electrocardiogram and chest radio-
graph. (Level of Evidence: C)
7. Initial 2-dimensional echocardiography with Dopp-
ler or radionuclide ventriculography to assess left
ventricular systolic function. (Level of Evidence: C)
8. Cardiac catheterization with coronary arteriography
in patients with angina who are candidates for
revascularization. (Level of Evidence: B)
Class IIa
1. Cardiac catheterization with coronary arteriography
in patients with chest pain who have not had
evaluation of their coronary anatomy and who have
no contraindications to coronary revascularization.
(Level of Evidence: C)
2. Cardiac catheterization with coronary arteriography
in patients with known or suspected coronary artery
disease but without angina who are candidates for
revascularization. (Level of Evidence: C)
3. Noninvasive imaging to detect ischemia and viabil-
ity in patients with known coronary artery disease
and no angina who are being considered for revas-
cularization. (Level of Evidence: C)
4. Maximal exercise testing with measurement of re-
spiratory gas exchange and/or blood oxygen satura-
tion to help determine whether HF is the cause of
exercise limitation when the contribution of HF is
uncertain. (Level of Evidence: C)
5. Maximal exercise testing with measurement of re-
spiratory gas exchange to identify high-risk patients
who are candidates for cardiac transplantation or
other advanced treatments. (Level of Evidence: B)
6. Echocardiography in asymptomatic first-degree rel-
atives of patients with idiopathic dilated cardiomy-
opathy. (Level of Evidence: C)
7. Repeat measurement of ejection fraction in patients
who have had a change in clinical status or who have
experienced or recovered from a clinical event or
received treatment that might have had a significant
effect on cardiac function. (Level of Evidence: C)
8. Screening for hemochromatosis. (Level of Evidence: C)
9. Measurement of serum antinuclear antibody, rheu-
matoid factor, urinary vanillylmandelic acid, and
metanephrines in selected patients. (Level of Evi-
dence: C)
Class IIb
1. Noninvasive imaging to define the likelihood of
coronary artery disease in patients with left ventric-
ular dysfunction. (Level of Evidence: C)
2. Maximal exercise testing with measurement of re-
spiratory gas exchange to facilitate prescription of
an appropriate exercise program. (Level of Evidence:
C)
3. Endomyocardial biopsy in patients in whom an
inflammatory or infiltrative disorder of the heart is
suspected. (Level of Evidence: C)
4. Assessment of human immunodeficiency virus sta-
tus. (Level of Evidence: C)
Class III
1. Endomyocardial biopsy in the routine evaluation of
patients with HF. (Level of Evidence: C)
2. Routine Holter monitoring or signal-averaged elec-
trocardiography. (Level of Evidence: C)
3. Repeat coronary arteriography or noninvasive test-
ing for ischemia in patients for whom coronary
artery disease has previously been excluded as the
cause of left ventricular dysfunction. (Level of Ev-
idence: C)
4. Routine measurement of circulating levels of nor-
epinephrine or endothelin. (Level of Evidence: C)
IV. THERAPY
A. Patients at High Risk of Developing
Left Ventricular Dysfunction (Stage A)
Many conditions or behaviors that are associated with an
increased risk of HF can be identified before patients show
any evidence of structural heart disease. Because early
modification of these factors can often reduce the risk of
HF, working with patients with these risk factors provides
the earliest opportunity to reduce the impact of HF on
public and individual health.
Recommendations for Patients at High Risk of
Developing HF (Stage A)
Class I
1. Control of systolic and diastolic hypertension in
accordance with recommended guidelines. (Level of
Evidence: A)
2. Treatment of lipid disorders in accordance with
recommended guidelines. (Level of Evidence: B)
3. Avoidance of patient behaviors that may increase
the risk of HF (e.g., smoking, alcohol consump-
tion, and illicit drug use). (Level of Evidence: C)
4. Angiotensin converting enzyme (ACE) inhibition
in patients with a history of atherosclerotic vascular
disease, diabetes mellitus, or hypertension and as-
sociated cardiovascular risk factors. (Level of Evi-
dence: B)
5. Control of ventricular rate in patients with supraven-
tricular tachyarrhythmias. (Level of Evidence: B)
6. Treatment of thyroid disorders. (Level of Evidence: C)
7. Periodic evaluation for signs and symptoms of HF.
(Level of Evidence: C)
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Class IIa
Noninvasive evaluation of left ventricular function in
patients with a strong family history of cardiomyop-
athy or in those receiving cardiotoxic interventions.
(Level of Evidence: C)
Class III
1. Exercise to prevent the development of HF. (Level
of Evidence: C)
2. Reduction of dietary salt beyond that which is
prudent for healthy individuals in patients without
hypertension or fluid retention. (Level of Evidence:
C)
3. Routine testing to detect left ventricular dysfunc-
tion in patients without signs or symptoms of HF
or evidence of structural heart disease. (Level of
Evidence: C)
4. Routine use of nutritional supplements to prevent
the development of structural heart disease. (Level
of Evidence: C)
B. Patients With Left Ventricular Dysfunction
Who Have Not Developed Symptoms (Stage B)
Patients without symptoms but who have had a myocardial
infarction and patients without symptoms who have evi-
dence of left ventricular dysfunction are at considerable risk
of developing HF. The likelihood of developing clinical HF
can be diminished by the use of therapies that reduce the
risk of additional injury, the process of remodeling, and the
progression of left ventricular dysfunction. However, as with
patients with no structural heart disease, there is no evidence
that control of dietary sodium, participation in regular
exercise, or use of nutritional supplements can prevent the
development of HF in patients with a recent or remote
myocardial infarction with or without left ventricular sys-
tolic dysfunction.
Recommendations for Patients With Asymptomatic
Left Ventricular Systolic Dysfunction (Stage B)
Class I
1. ACE inhibition in patients with a recent or remote
history of myocardial infarction regardless of ejec-
tion fraction. (Level of Evidence: A)
2. ACE inhibition in patients with a reduced ejection
fraction, whether or not they have experienced a
myocardial infarction. (Level of Evidence: B)
3. Beta-blockade in patients with a recent myocardial
infarction regardless of ejection fraction. (Level of
Evidence: A)
4. Beta-blockade in patients with a reduced ejection
fraction, whether or not they have experienced a
myocardial infarction. (Level of Evidence: B)
5. Valve replacement or repair for patients with he-
modynamically significant valvular stenosis or re-
gurgitation. (Level of Evidence: B)
6. Regular evaluation for signs and symptoms of HF.
(Level of Evidence: C)
7. Measures listed as class I recommendations for
patients in stage A. (Levels of Evidence: A, B, and C
as appropriate).
Class IIb
Long-term treatment with systemic vasodilators in
patients with severe aortic regurgitation. (Level of
Evidence: B)
Class III
1. Treatment with digoxin in patients with left ven-
tricular dysfunction who are in sinus rhythm. (Level
of Evidence: C)
2. Reduction of dietary salt beyond that which is prudent
for healthy individuals in patients without hyperten-
sion or fluid retention. (Level of Evidence: C)
3. Exercise to prevent the development of HF. (Level
of Evidence: C)
4. Routine use of nutritional supplements to treat
structural heart disease or prevent the development
of symptoms of HF. (Level of Evidence: C)
C. Patients With Left Ventricular Dysfunction
With Current or Prior Symptoms (Stage C)
1. General Measures. Measures listed as class I recom-
mendations for patients in stages A and B are also appro-
priate for patients with current or prior symptoms of HF
(see Section V). In addition, moderate sodium restriction is
indicated, along with daily measurement of weight, to
permit effective use of lower and safer doses of diuretic
drugs. Immunization with influenza and pneumococcal
vaccines may reduce the risk of a respiratory infection.
Although most patients should not participate in heavy
labor or exhaustive sports, physical activity should be en-
couraged, except during periods of acute decompensation or
in patients with suspected myocarditis, because restriction of
activity promotes physical deconditioning, which may ad-
versely affect clinical status and contribute to the exercise
intolerance of patients with HF (13–16).
Of the general measures that should be pursued in
patients with HF, possibly the most effective yet least
utilized is close attention and follow-up. Noncompliance
with diet and medications can rapidly and profoundly affect
the clinical status of patients, and increases in body weight
and minor changes in symptoms commonly precede the
major clinical episodes that require emergency care or
hospitalization. Patient education and close supervision,
which includes surveillance by the patient and his or her
family between physician visits, can reduce the likelihood of
noncompliance and can often lead to the detection of
changes in body weight or clinical status early enough to
allow the patient or a healthcare provider an opportunity to
institute treatments that can prevent clinical deterioration
and hospitalization. Supervision between physician visits
ideally may be performed by a nurse or physician assistant
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with special training in the care of patients with HF. Such
an approach has been reported to have significant clinical
benefits (17–20).
2. Drugs Recommended for Routine Use. Most patients
with symptomatic left ventricular dysfunction should be
routinely managed with a combination of 4 types of drugs:
a diuretic, an ACE inhibitor, a beta-adrenergic blocker, and
(usually) digitalis (21). The value of these drugs has been
established in numerous large-scale clinical trials, and the
evidence supporting a central role for their use is compelling
and persuasive. Patients with evidence of fluid retention
should be given a diuretic until a euvolemic state is achieved,
and diuretic therapy should be continued to prevent the
recurrence of fluid retention. Even if the patient has
responded favorably to the diuretic, treatment with an ACE
inhibitor and a beta-blocker should be initiated and main-
tained in patients who can tolerate them, because they have
been shown to favorably influence the long-term prognosis
of HF. Therapy with digoxin may be initiated at any time to
reduce symptoms and enhance exercise tolerance.
3. Interventions to Be Considered for Use in Selected
Patients. Several interventions have been shown in con-
trolled clinical trials to be useful in a limited cohort of patients
with HF. Some of these are undergoing active investigation in
large-scale trials to determine whether their role in the man-
agement of HF might justifiably be expanded. They include
aldosterone antagonists, angiotensin receptor blockers, hydral-
azine and isosorbide dinitrate, and exercise training.
4. Drugs and Interventions Under Active Investigation.
Several drugs and interventions are under active evaluation
in long-term large-scale trials because they showed promise
in pilot studies that involved small numbers of patients.
Until the results of definitive trials are available, none of
these interventions can be recommended for use in patients
with HF. These include vasopeptidase inhibitors, cytokine
antagonists, endothelin antagonists, synchronized biven-
tricular pacing, external counterpulsation, and techniques
for respiratory support.
5. Interventions of Unproved Value and Not Recom-
mended. Interventions of unproved value that are not
recommended include nutritional supplements and hor-
monal therapies, intermittent intravenous positive inotropic
therapy, and dynamic cardiomyoplasty.
Recommendations for Treatment of Symptomatic
Left Ventricular Systolic Dysfunction (Stage C)
Class I
1. Diuretics in patients who have evidence of fluid
retention. (Level of Evidence: A)
2. ACE inhibition in all patients unless contraindi-
cated. (Level of Evidence: A)
3. Beta-adrenergic blockade in all stable patients un-
less contraindicated. Patients should have no or
minimal evidence of fluid retention and should not
have required treatment recently with an intrave-
nous positive inotropic agent. (Level of Evidence: A)
4. Digitalis for the treatment of symptoms of HF,
unless contraindicated. (Level of Evidence: A)
5. Withdrawal of drugs known to adversely affect the
clinical status of patients (e.g., nonsteroidal anti-
inflammatory drugs, most antiarrhythmic drugs,
and most calcium channel blocking drugs). (Level of
Evidence: B)
6. Measures listed as class I recommendations for
patients in stages A and B (Levels of Evidence: A, B,
and C as appropriate).
Class IIa
1. Spironolactone in patients with recent or current
class IV symptoms, preserved renal function, and a
normal potassium concentration. (Level of Evi-
dence: B)
2. Exercise training as an adjunctive approach to
improve clinical status in ambulatory patients.
(Level of Evidence: A)
3. Angiotensin receptor blockade in patients who are
being treated with digitalis, diuretics, and a beta-
blocker and who cannot be given an ACE inhibitor
because of cough or angioedema. (Level of Evidence: A)
4. A combination of hydralazine and a nitrate in
patients who are being treated with digitalis, diuret-
ics, and a beta-blocker and who cannot be given an
ACE inhibitor because of hypotension or renal
insufficiency. (Level of Evidence: B)
Class IIb
1. Addition of an angiotensin receptor blocker to an
ACE inhibitor. (Level of Evidence: B)
2. Addition of a nitrate, alone or in combination with
hydralazine, to an ACE inhibitor in patients who
are also being given digitalis, diuretics, and a
beta-blocker. (Level of Evidence: B)
Class III
1. Long-term intermittent use of an infusion of a
positive inotropic drug. (Level of Evidence: C)
2. Use of an angiotensin receptor blocker instead of an
ACE inhibitor in patients with HF who have not
been given or who can tolerate an ACE inhibitor.
(Level of Evidence: B)
3. Use of an angiotensin receptor blocker before a
beta-blocker in patients with HF who are taking an
ACE inhibitor. (Level of Evidence: A)
4. Use of a calcium channel blocking drug as a treat-
ment for HF. (Level of Evidence: B)
5. Routine use of nutritional supplements (coenzyme
Q10, carnitine, taurine, and antioxidants) or hor-
monal therapies (growth hormone or thyroid hor-
mone) for the treatment of HF. (Level of Evidence: C)
D. Patients With Refractory End-Stage HF (Stage D)
Most patients with HF due to left ventricular systolic
dysfunction respond favorably to pharmacological and non-
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pharmacological treatments and enjoy a good quality of life
and enhanced survival. However, despite optimal medical
therapy, some patients do not improve with treatment or
experience rapid recurrence of symptoms. Such patients
generally have symptoms (including profound fatigue) at
rest or on minimal exertion, cannot perform most activities
of daily living, frequently have evidence of cardiac cachexia,
and typically require repeated or prolonged hospitalizations
for intensive management. These individuals represent the
most advanced state of HF and should be considered for
specialized treatment strategies such as mechanical circula-
tory support, continuous intravenous positive inotropic
therapy, referral for cardiac transplantation, or hospice care.
Before a patient is considered to have refractory HF, it is
critical that physicians confirm the accuracy of the diagno-
sis; identify and reverse, if possible, any contributing con-
ditions; and ensure that all conventional medical strategies
have been optimally employed.
Many patients with advanced HF have symptoms that are
related to the retention of salt and water and thus will
respond favorably to interventions designed to restore so-
dium balance. Hence, a critical step in the successful
management of end-stage HF is the recognition and me-
ticulous control of fluid retention.
Controlled trials suggest that patients with advanced HF
respond favorably to treatment with both ACE inhibitors
and beta-blockers in a manner similar to those with mild to
moderate disease (22,23). However, because neurohormonal
mechanisms play an important role in the support of
circulatory homeostasis as HF progresses, neurohormonal
antagonism may be less well tolerated by patients with
severe symptoms than by patients with mild symptoms.
Patients who are at the end stage of their disease are at
particular risk of developing hypotension and renal insuffi-
ciency after the administration of an ACE inhibitor and of
experiencing worsening HF after treatment with a beta-
blocker. As a result, patients with refractory HF may
tolerate only small doses of these neurohormonal antago-
nists or may not tolerate them at all.
Many commonly performed cardiac surgical procedures
(e.g., coronary artery bypass grafting and valve repair/
replacement) are being performed with increasing frequency
in patients with HF, including those with advanced symp-
toms. Revascularization is routinely recommended for pa-
tients with left ventricular dysfunction who have angina, but
its role in patients without symptoms of ischemia remains
controversial.
Cardiac transplantation is currently the only established
surgical approach to the treatment of refractory HF, but it
is available to no more than 2500 patients yearly in the
United States (24). Alternative surgical and mechanical
approaches for the treatment of end-stage HF are under
development. Extracorporeal devices are approved for cir-
culatory support in patients who are expected to recover
from a major cardiac insult (e.g., postcardiotomy shock) or
who are expected to receive a definitive treatment for HF
(e.g., heart transplantation). Left ventricular assist devices
provide similar degrees of hemodynamic support, but many
are implantable and thus allow for patient ambulation and
hospital discharge (25,26). One ongoing trial is evaluating
the long-term utility of such a device in patients with
refractory HF who are not candidates for a heart transplant.
Recommendations for Patients With Refractory
End-Stage HF (Stage D)
Class I
1. Meticulous identification and control of fluid re-
tention. (Level of Evidence: B)
2. Referral for cardiac transplantation in eligible pa-
tients. (Level of Evidence: B)
3. Referral to an HF program with expertise in the
management of refractory HF. (Level of Evidence: A)
4. Measures listed as class I recommendations for
patients in stages A, B, and C. (Levels of Evidence:
A, B, and C as appropriate).
Class IIb
1. Pulmonary artery catheter placement to guide ther-
apy in patients with persistently severe symptoms.
(Level of Evidence: C)
2. Mitral valve repair or replacement for severe sec-
ondary mitral regurgitation. (Level of Evidence: C)
3. Continuous intravenous infusion of a positive ino-
tropic agent for palliation of symptoms. (Level of
Evidence: C)
Class III
1. Partial left ventriculectomy. (Level of Evidence: C)
2. Routine intermittent infusions of positive inotropic
agents. (Level of Evidence: B)
V. TREATMENT OF SPECIAL POPULATIONS
AND CONCOMITANT DISORDERS
Many patients with HF are members of subpopulations or
have comorbid conditions that either contribute to the
development of their HF or make the management of their
HF symptoms more difficult. These factors need to be
considered in the management of such patients.
1. Special Subpopulations. Many subgroups are underrep-
resented in most trials, and some present unique problems
in HF management. These include women and men, racial
minorities, and elderly patients.
2. Concomitant Disorders. Patients with left ventricular
dysfunction frequently have associated cardiovascular and
noncardiovascular disorders, the course or treatment of
which may exacerbate the syndrome of HF. In many
patients, appropriate management of these concomitant
illnesses may produce clinical and prognostic benefits that
may be as important as the treatment of HF itself. These
concomitant conditions include cardiovascular disorders
such as hypertension, hyperlipidemia, and diabetes mellitus;
coronary artery disease; supraventricular arrhythmias; ven-
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tricular arrhythmias and prevention of sudden death; and
prevention of thrombotic events. Associated noncardiovas-
cular disorders include renal insufficiency, pulmonary dis-
ease, cancer, and thyroid disease.
Recommendations for Management of Concomitant
Diseases in Patients With HF
Class I
1. Control of systolic and diastolic hypertension in
patients with HF in accordance with recommended
guidelines. (Level of Evidence: A)
2. Nitrates and beta-blockers (in conjunction with
diuretics) for the treatment of angina in patients
with HF. (Level of Evidence: B)
3. Coronary revascularization in patients who have
both HF and angina. (Level of Evidence: A)
4. Anticoagulants in patients with HF who have par-
oxysmal or chronic atrial fibrillation or a previous
thromboembolic event. (Level of Evidence: A)
5. Control of the ventricular response in patients with
HF and atrial fibrillation with a beta-blocker (or
amiodarone, if the beta-blocker is contraindicated
or not tolerated). (Level of Evidence: A)
6. Beta-adrenergic blockade (unless contraindicated)
in patients with HF to reduce the risk of sudden
death. Patients should have no or minimal fluid
retention and should not have recently required
treatment with an intravenous positive inotropic
agent. (Level of Evidence: A)
7. Implantable cardioverter-defibrillator, alone or in
combination with amiodarone, in patients with HF
who have a history of sudden death, ventricular
fibrillation, or hemodynamically destabilizing ven-
tricular tachycardia. (Level of Evidence: A)
Class IIa
1. Antiplatelet agents for prevention of myocardial
infarction and death in patients with HF who have
underlying coronary artery disease. (Level of Evi-
dence: B)
2. Digitalis to control the ventricular response in
patients with HF and atrial fibrillation. (Level of
Evidence: A)
Class IIb
1. Coronary revascularization in patients who have
HF and coronary artery disease but no angina.
(Level of Evidence: B)
2. Restoration of sinus rhythm by electrical cardiover-
sion in patients with HF and atrial fibrillation.
(Level of Evidence: C)
3. Amiodarone to prevent sudden death in patients
with HF and asymptomatic ventricular arrhyth-
mias. (Level of Evidence: B)
4. Anticoagulation in patients with HF who do not
have atrial fibrillation or a previous thromboem-
bolic event. (Level of Evidence: B or C)
Class III
1. Routine use of an implantable cardioverter-
defibrillator in patients with HF. (Level of Evidence: C)
2. Class I or III antiarrhythmic drugs (except amio-
darone) in patients with HF for the prevention or
treatment of asymptomatic ventricular arrhythmias.
(Level of Evidence: A)
3. Ambulatory electrocardiographic monitoring for
the detection of asymptomatic ventricular arrhyth-
mias. (Level of Evidence: A)
VI. DIASTOLIC DYSFUNCTION
Approximately 20% to 40% of patients with HF have
preserved left ventricular systolic function and (in the
absence of valvular disease) are believed to have an impair-
ment of ventricular relaxation as the primary mechanism
leading to symptoms (27–31). Several recognized myocar-
dial disorders are associated with diastolic dysfunction,
including restrictive cardiomyopathy, obstructive and non-
obstructive hypertrophic cardiomyopathy, and infiltrative
cardiomyopathies. However, the vast majority of patients
who present with HF and normal systolic function do not
have a defined myocardial disease but nevertheless have a
clinically significant impairment of diastolic function.
Many of the changes that occur in the cardiovascular
system as a result of aging have a greater impact on diastolic
function than on systolic performance (32). HF associated
with preserved systolic function is primarily a disease of
elderly women, most of whom have hypertension (28).
These patients suffer considerably from dyspnea and fatigue,
which can limit their exercise tolerance and quality of life,
and they are hospitalized frequently for clinical stabilization
(33). Although the risk of death in these patients appears to
be lower than in patients with HF and poor systolic
function, the management of these patients still has major
socioeconomic implications (34).
It is difficult to be precise about the diagnosis of diastolic
dysfunction. Noninvasive methods, especially those that rely
on Doppler echocardiography, have been developed to assist
in such diagnosis. In practice, however, the diagnosis of
diastolic HF is generally based on the finding of typical
symptoms and signs of HF in a patient who is shown to
have a normal left ventricular ejection fraction and no
valvular abnormalities on echocardiography.
In contrast to the treatment of HF due to systolic
dysfunction, few clinical trials are available to guide the
management of patients with HF due to diastolic dysfunc-
tion. Although controlled studies have been performed with
digitalis, ACE inhibitors, angiotensin receptor antagonists,
beta-blockers, and calcium channel blockers in patients with
HF who had a normal left ventricular ejection fraction,
these trials have been small or have produced inconclusive
results (35–39). Nevertheless, many patients with diastolic
HF receive treatment with these drugs because of the
presence of comorbid conditions (i.e., atrial fibrillation,
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hypertension, diabetes, or coronary artery disease). In addi-
tion, recommendations regarding the use of anticoagulation
and antiarrhythmic agents apply to both systolic and dia-
stolic HF.
In the absence of controlled clinical trials, the manage-
ment of patients with diastolic dysfunction is frequently
determined by a set of therapeutic principles (31). These
include control of blood pressure, control of tachycardia,
reduction in central blood volume, and alleviation of myo-
cardial ischemia.
Recommendations for Management of HF and
Preserved Systolic Function
Class I
1. Control of systolic and diastolic hypertension in
accordance with published guidelines. (Level of
Evidence: A)
2. Control of ventricular rate in patients with atrial
fibrillation. (Level of Evidence: C)
3. Diuretics to control pulmonary congestion and
peripheral edema. (Level of Evidence: C)
Class IIa
Coronary revascularization in patients with coronary
artery disease in whom symptomatic or demonstrable
myocardial ischemia is judged to have an adverse
effect on diastolic function. (Level of Evidence: C)
Class IIb
1. Restoration of sinus rhythm in patients with atrial
fibrillation. (Level of Evidence: C)
2. Use of beta-adrenergic blocking agents, ACE in-
hibitors, angiotensin receptor blockers, or calcium
antagonists in patients with controlled hyperten-
sion to minimize symptoms of HF. (Level of Evi-
dence: C)
3. Digitalis to minimize symptoms of HF. (Level of
Evidence: C)
VII. END-OF-LIFE CONSIDERATIONS
Although issues surrounding end-of-life care deserve atten-
tion for all chronic terminal diseases, several general prin-
ciples merit particular discussion in the context of chronic
HF (40,41). Education of both patient and family regarding
the expected or anticipated course of illness, final treatment
options, and planning should be undertaken before the
patient becomes too ill to participate in decisions. Discus-
sions regarding treatment preferences, living wills, and
advance directives should encompass a variety of likely
contingencies that include responses to a potentially revers-
ible exacerbation of HF, a cardiac arrest, a sudden cata-
strophic event such as a severe cerebrovascular accident, and
worsening of major coexisting noncardiac conditions. In
reviewing these issues with families, short-term intervention
in anticipation of rapid recovery should be distinguished
from prolonged life support without reasonable expectation
of return to good functional capacity.
Hospice services have only recently been extended to
patients dying of HF. Originally developed for patients with
end-stage cancer, the focus of hospice care has now been
expanded to the relief of symptoms other than pain (42).
This is appropriate, because the suffering of patients with
HF is characteristically linked to symptoms of breathless-
ness, and thus, compassionate care may require the frequent
administration of intravenous diuretics and (in some cases)
the continuous infusion of positive inotropic agents rather
than the use of potent analgesics. Physicians caring for these
patients, however, are becoming more comfortable with the
prescription of anxiolytics and narcotics to ease distress
during the last days.
Recommendations for End-of-Life Care
Class I
1. Ongoing patient and family education regarding
prognosis for function and survival. (Level of Evi-
dence: C)
2. Patient and family education about options for
formulating and implementing advance directives.
(Level of Evidence: C)
3. Continuity of medical care between inpatient and
outpatient settings. (Level of Evidence: C)
4. Components of hospice care that are appropriate to
the relief of suffering. (Level of Evidence: C)
Class III
Implantation of a cardioverter-defibrillator in pa-
tients with class IV symptoms who are not anticipated
to experience clinical improvement from available
treatments. (Level of Evidence: C)
VIII. IMPLEMENTATION OF PRACTICE GUIDELINES
Despite the publication of evidence-based guidelines
(6,21,43), the current care of patients with HF remains
suboptimal. Numerous studies document underutilization
of key processes of care, such as use of ACE inhibitors in
patients with decreased systolic function and the measure-
ment of left ventricular ejection fraction (44–46). The
relatively sparse literature on implementing practice guide-
lines for patients with HF can be divided into 2 areas:
isolated provider interventions and disease-management
systems approaches. It is clear that dissemination of a
practice guideline must be accompanied by more intensive
educational and behavioral change efforts to maximize the
chances of improving physician practice patterns. The
disease-management approach views HF as a chronic illness
spanning the home, outpatient, and inpatient settings and
involves multidisciplinary team care. Observational and
randomized controlled trials have generally shown that
disease-management programs reduce hospitalizations and
can improve quality of life and functional status (20,47).
Insufficient evidence exists to make uniform recommen-
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dations about the most appropriate roles for generalist
physicians and cardiologists in the care of patients with HF.
Many questions remain. Do generalist physicians and car-
diologists provide similar levels of care for the noncardiac
comorbid conditions frequently present in patients with
HF? What is the optimal time for referral to a specialist?
What is the most effective system of comanagement of
patients by generalists and cardiologists? What is the most
cost-effective entry point into a disease-management pro-
gram? Regardless of the ultimate answers to these questions,
all physicians and other healthcare providers must advocate
and follow care practices that have been shown to improve
patient outcomes. If a physician is not comfortable follow-
ing a specific recommendation (e.g., the use of beta-
blockers), then the physician should refer the patient to
someone with expertise in HF. A collaborative model in
which generalist and specialist physicians work together to
optimize the care of patients with HF is likely to be most
fruitful.
Recommendations for Implementing Practice
Guidelines
Class I
1. Multifactorial interventions that attack different
barriers to behavioral change. (Level of Evidence: A)
2. Multidisciplinary disease-management programs
for patients at high risk for hospital admission or
clinical deterioration. (Level of Evidence: B)
3. Academic detailing or educational outreach visits.
(Level of Evidence: A)
Class IIa
1. Chart audit and feedback of results. (Level of
Evidence: A)
2. Reminder systems. (Level of Evidence: A)
3. Local opinion leaders. (Level of Evidence: A)
Class IIb
Multidisciplinary disease-management programs for
patients at low risk for hospital admission or clinical
deterioration. (Level of Evidence: B)
Class III
1. Dissemination of guidelines without more inten-
sive behavioral change efforts. (Level of Evidence: A)
2. Basic provider education alone. (Level of Evidence: A)
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